Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 Shares

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 4,600 shares of the firm’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the transaction, the director now directly owns 57,160 shares of the company’s stock, valued at approximately $484,716.80. This represents a 7.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Novavax Trading Up 6.6 %

Shares of Novavax stock traded up $0.53 during trading hours on Thursday, reaching $8.57. The stock had a trading volume of 3,813,721 shares, compared to its average volume of 9,060,255. The stock’s 50 day moving average is $8.74 and its 200 day moving average is $11.40. Novavax, Inc. has a twelve month low of $3.53 and a twelve month high of $23.86. The firm has a market capitalization of $1.37 billion, a PE ratio of -3.79 and a beta of 2.02.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. The firm’s revenue for the quarter was down 54.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.26) earnings per share. As a group, sell-side analysts predict that Novavax, Inc. will post -1.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. B. Riley reissued a “buy” rating and issued a $26.00 price objective (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday, December 10th. Finally, Jefferies Financial Group dropped their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.83.

Institutional Investors Weigh In On Novavax

Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of Novavax by 34.3% in the second quarter. Bank of New York Mellon Corp now owns 533,942 shares of the biopharmaceutical company’s stock valued at $6,760,000 after acquiring an additional 136,472 shares in the last quarter. Signaturefd LLC raised its stake in Novavax by 214.5% in the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 3,874 shares during the last quarter. Banque Cantonale Vaudoise grew its holdings in shares of Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 2,500 shares in the last quarter. Rhumbline Advisers raised its position in shares of Novavax by 39.2% in the second quarter. Rhumbline Advisers now owns 199,909 shares of the biopharmaceutical company’s stock valued at $2,531,000 after buying an additional 56,324 shares during the last quarter. Finally, Midland Wealth Advisors LLC purchased a new position in shares of Novavax in the second quarter worth about $152,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.